Core Viewpoint - iRobot Corporation is under investigation for potential securities fraud and unlawful business practices following a significant financial loss reported in its fourth quarter and full year 2024 results [1][2]. Financial Performance - For Q4 2024, iRobot reported a loss of $2.06 per share on revenue of $172 million, marking a 44% year-over-year decline [2]. - The company expressed substantial doubt about its ability to continue as a going concern for at least 12 months due to uncertainties surrounding new product launches and market conditions [2]. Stock Market Reaction - Following the financial report, iRobot's stock price dropped by $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [2]. Legal Context - Pomerantz LLP is investigating claims on behalf of iRobot investors, indicating potential legal ramifications for the company and its officers [1].

Core Viewpoint - Pliant Therapeutics is under investigation for potential securities fraud following significant stock price declines related to the discontinuation of its BEACON-IPF Phase 2b trial for bexotegrast, raising concerns about the company's future prospects [1][2][4]. Group 1: Company Actions and Responses - On February 7, 2025, Pliant announced a voluntary pause in enrollment and dosing for the BEACON-IPF Phase 2b trial based on recommendations from the independent Data Safety Monitoring Board (DSMB) [2]. - Following the announcement on February 7, Pliant's stock price dropped by $4.72, or 60.59%, closing at $3.07 per share on February 10, 2025 [3]. - On March 3, 2025, Pliant disclosed the discontinuation of the BEACON-IPF trial due to an imbalance in unadjudicated IPF-related adverse events between treatment and placebo groups, as recommended by both the DSMB and an outside expert panel [4]. - After the March 3 announcement, Pliant's stock price fell by $2.06, or 59.88%, closing at $1.38 per share [5]. Group 2: Market Reactions - Analysts from Wells Fargo and Citi downgraded Pliant's stock following the February 7 announcement, citing uncertainty regarding the future of bexotegrast [2].

Core Viewpoint - Parsons Corporation is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q4 2024, which led to a significant drop in stock price [1][2]. Financial Performance - On February 19, 2025, Parsons reported Q4 2024 financial results that fell short of prior guidance for both revenue and EBITDA [2]. - The adjusted EBITDA growth for the quarter was negatively impacted by $29 million due to adjustments on two programs [2]. - Following the announcement, Parsons' stock price decreased by $8.42 per share, or 11.46%, closing at $65.08 per share [2]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or other unlawful business practices by Parsons and its officers and/or directors [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3].

Core Viewpoint - Freshpet, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results that led to a significant drop in stock price [1][2]. Financial Performance - On February 20, 2025, Freshpet reported its financial results for Q4 and the full year ended December 31, 2024, which included sales and profits that did not meet consensus expectations [2]. - Following the announcement, Freshpet's stock price decreased by $24.18 per share, or 18.53%, closing at $106.38 per share on the same day [2]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Freshpet investors regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3].

NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Merck and certain of its officers and/or d ...